ZA969646B - Protein kinase C inhibitor. - Google Patents
Protein kinase C inhibitor.Info
- Publication number
- ZA969646B ZA969646B ZA9609646A ZA969646A ZA969646B ZA 969646 B ZA969646 B ZA 969646B ZA 9609646 A ZA9609646 A ZA 9609646A ZA 969646 A ZA969646 A ZA 969646A ZA 969646 B ZA969646 B ZA 969646B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitor
- protein kinase
- kinase
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US697095P | 1995-11-20 | 1995-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA969646B true ZA969646B (en) | 1998-05-18 |
Family
ID=21723527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9609646A ZA969646B (en) | 1995-11-20 | 1996-11-18 | Protein kinase C inhibitor. |
Country Status (34)
Country | Link |
---|---|
US (3) | US5710145A (pt) |
EP (1) | EP0776895B1 (pt) |
JP (1) | JP3348859B2 (pt) |
KR (1) | KR100304210B1 (pt) |
CN (1) | CN1093759C (pt) |
AR (2) | AR004336A1 (pt) |
AT (1) | ATE172199T1 (pt) |
AU (1) | AU711125B2 (pt) |
BR (1) | BR9611724A (pt) |
CA (1) | CA2237221C (pt) |
CO (1) | CO4750823A1 (pt) |
CY (1) | CY2103B1 (pt) |
CZ (1) | CZ297524B6 (pt) |
DE (1) | DE69600784T2 (pt) |
DK (1) | DK0776895T3 (pt) |
EA (1) | EA000967B1 (pt) |
EG (1) | EG23871A (pt) |
ES (1) | ES2122764T3 (pt) |
HU (1) | HU226821B1 (pt) |
IL (1) | IL124417A (pt) |
MX (1) | MX9803792A (pt) |
MY (1) | MY118068A (pt) |
NO (1) | NO310196B1 (pt) |
NZ (1) | NZ323571A (pt) |
PE (1) | PE22798A1 (pt) |
PL (1) | PL184715B1 (pt) |
RO (1) | RO120074B1 (pt) |
SI (1) | SI0776895T1 (pt) |
TR (1) | TR199800759T2 (pt) |
TW (1) | TW403754B (pt) |
UA (1) | UA61897C2 (pt) |
WO (1) | WO1997018809A1 (pt) |
YU (1) | YU49315B (pt) |
ZA (1) | ZA969646B (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
AR017200A1 (es) | 1997-12-23 | 2001-08-22 | Astrazeneca Ab | Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos |
US6620977B1 (en) * | 1998-01-30 | 2003-09-16 | Daiso Co., Ltd. | Process for producing butanetriol derivative |
US6291446B1 (en) * | 1998-03-05 | 2001-09-18 | Eli Lilly And Company | Therapeutic treatment for cytomegalovirus infection |
US6103713A (en) * | 1998-03-05 | 2000-08-15 | Eli Lilly And Company | Therapeutic treatment for autoimmune diseases |
US6225301B1 (en) | 1998-03-05 | 2001-05-01 | Eli Lilly And Company | Therapeutic treatment for renal dysfunction |
US6103712A (en) * | 1998-03-05 | 2000-08-15 | Eli Lilly And Company | Therapeutic treatment for asthma |
SE9800835D0 (sv) | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
AU758241B2 (en) * | 1998-03-13 | 2003-03-20 | University Of British Columbia, The | Granulatimide derivatives for use in cancer treatment |
CA2245029A1 (en) | 1998-03-13 | 1999-09-13 | University Of British Columbia | Granulatimide compounds as g2 checkpoint inhibitors |
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
US6127401A (en) | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
TWI223598B (en) * | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
GB9828640D0 (en) * | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
US6492406B1 (en) | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
US6284783B1 (en) | 1999-06-09 | 2001-09-04 | The Uab Research Foundation | Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis |
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
US7087613B2 (en) * | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
US6852688B2 (en) | 2000-03-10 | 2005-02-08 | University Of Florida | Compositions for treating diabetic retinopathy and methods of using same |
US20030224415A1 (en) * | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
CA2413156C (en) * | 2000-07-03 | 2009-08-18 | Gala Design, Inc. | Expression vectors |
AU2001271614B2 (en) | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
US6300106B1 (en) * | 2000-11-22 | 2001-10-09 | Ppg Industries Ohio, Inc. | Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate |
US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
US20040038304A1 (en) * | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
JP2005531544A (ja) * | 2002-05-06 | 2005-10-20 | ワシントン・ユニバーシティ | Egfr経路の抑制による緑内障およびnos−2発現により媒介される他の状態の治療方法 |
DE10244453A1 (de) * | 2002-09-24 | 2004-04-01 | Phenomiques Gmbh | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
US7232842B2 (en) * | 2003-01-10 | 2007-06-19 | Board Of Trustees Of The Leland Stanford Junior University | Kinase inhibitors and associated pharmaceutical compositions and methods of use |
WO2004111077A1 (en) | 2003-06-18 | 2004-12-23 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor |
US20050152942A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US20050221429A1 (en) * | 2004-01-16 | 2005-10-06 | Cardinal Health Pts, Llc | Host cells containing multiple integrating vectors comprising an amplifiable marker |
WO2005087210A2 (en) * | 2004-03-17 | 2005-09-22 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
DE102004019413A1 (de) * | 2004-04-19 | 2005-11-24 | Phenos Gmbh | Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten |
WO2006071451A2 (en) * | 2004-12-03 | 2006-07-06 | The Regents Of The University Of California | Compounds that prevent macrophage apoptosis and uses thereof |
WO2006068988A1 (en) * | 2004-12-20 | 2006-06-29 | Eli Lilly And Company | Combination therapy for vascular complications associated with hyperglycemia |
US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
EP1877424A4 (en) * | 2005-04-11 | 2010-09-29 | Pharmagap Inc | INHIBITORS OF PROTEIN KINASES AND USES THEREOF |
WO2008027619A2 (en) | 2006-09-01 | 2008-03-06 | Intermec Ip Corp. | Rfid tag system with block coding, such as space-time block coding |
AR069799A1 (es) * | 2007-12-21 | 2010-02-17 | Novartis Ag | Composicion farmaceutica |
EP2181999A1 (en) | 2008-11-03 | 2010-05-05 | Zentiva, A.S. | Method of manufacturing ruboxistarin |
US9265764B2 (en) * | 2009-02-27 | 2016-02-23 | Massachusetts Institute Of Technology | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
EP2552428A1 (en) | 2010-03-30 | 2013-02-06 | Novartis AG | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
CN104812415A (zh) | 2012-11-29 | 2015-07-29 | 诺华股份有限公司 | 药物组合 |
WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
BR112019012383A2 (pt) | 2016-12-19 | 2020-02-27 | Chromaderm, Inc. | Métodos de tratamento de distúrbios de hiperpigmentação |
WO2018175340A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
SG11202000730QA (en) | 2017-07-28 | 2020-02-27 | Applied Therapeutics Inc | Compositions and methods for treating galactosemia |
BR112022021845A2 (pt) | 2020-05-01 | 2022-12-20 | Applied Therapeutics Inc | Inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase |
KR20230128175A (ko) * | 2022-02-25 | 2023-09-04 | 주식회사 온코크로스 | 루복시스타우린을 포함하는 항암용 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL89167A (en) * | 1988-02-10 | 1994-02-27 | Hoffmann La Roche | Substituted pyrroles, their manufacture and pharmaceutical compositions containing them |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
WO1994007895A1 (en) * | 1992-09-25 | 1994-04-14 | Schering Corporation | Diindolo compounds and pharmaceutical compositions containing them |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
ATE204579T1 (de) | 1993-12-07 | 2001-09-15 | Lilly Co Eli | Proteinkinase c-inhibitoren |
-
1996
- 1996-11-18 SI SI9630038T patent/SI0776895T1/xx unknown
- 1996-11-18 PL PL96326754A patent/PL184715B1/pl not_active IP Right Cessation
- 1996-11-18 PE PE1996000829A patent/PE22798A1/es not_active Application Discontinuation
- 1996-11-18 HU HU9903377A patent/HU226821B1/hu not_active IP Right Cessation
- 1996-11-18 JP JP51983697A patent/JP3348859B2/ja not_active Expired - Fee Related
- 1996-11-18 DK DK96308318T patent/DK0776895T3/da active
- 1996-11-18 TW TW085114103A patent/TW403754B/zh not_active IP Right Cessation
- 1996-11-18 WO PCT/US1996/018512 patent/WO1997018809A1/en active IP Right Grant
- 1996-11-18 AT AT96308318T patent/ATE172199T1/de active
- 1996-11-18 US US08/749,607 patent/US5710145A/en not_active Expired - Lifetime
- 1996-11-18 EA EA199800374A patent/EA000967B1/ru not_active IP Right Cessation
- 1996-11-18 IL IL12441796A patent/IL124417A/en not_active IP Right Cessation
- 1996-11-18 RO RO98-00955A patent/RO120074B1/ro unknown
- 1996-11-18 BR BR9611724A patent/BR9611724A/pt not_active Application Discontinuation
- 1996-11-18 CA CA002237221A patent/CA2237221C/en not_active Expired - Fee Related
- 1996-11-18 UA UA98052515A patent/UA61897C2/uk unknown
- 1996-11-18 AU AU10548/97A patent/AU711125B2/en not_active Ceased
- 1996-11-18 ZA ZA9609646A patent/ZA969646B/xx unknown
- 1996-11-18 YU YU60996A patent/YU49315B/sh unknown
- 1996-11-18 EP EP96308318A patent/EP0776895B1/en not_active Expired - Lifetime
- 1996-11-18 DE DE69600784T patent/DE69600784T2/de not_active Expired - Lifetime
- 1996-11-18 KR KR1019980703622A patent/KR100304210B1/ko not_active IP Right Cessation
- 1996-11-18 TR TR1998/00759T patent/TR199800759T2/xx unknown
- 1996-11-18 NZ NZ323571A patent/NZ323571A/xx not_active IP Right Cessation
- 1996-11-18 ES ES96308318T patent/ES2122764T3/es not_active Expired - Lifetime
- 1996-11-18 CZ CZ0150298A patent/CZ297524B6/cs not_active IP Right Cessation
- 1996-11-18 CN CN96198420A patent/CN1093759C/zh not_active Expired - Lifetime
- 1996-11-19 CO CO96060835A patent/CO4750823A1/es unknown
- 1996-11-19 MY MYPI96004799A patent/MY118068A/en unknown
- 1996-11-19 EG EG102296A patent/EG23871A/xx active
- 1996-11-20 AR ARP960105254A patent/AR004336A1/es not_active Application Discontinuation
- 1996-11-20 AR ARP960105255A patent/AR004717A1/es not_active Application Discontinuation
-
1997
- 1997-11-07 US US08/966,081 patent/US6015807A/en not_active Expired - Lifetime
-
1998
- 1998-05-13 NO NO19982182A patent/NO310196B1/no not_active IP Right Cessation
- 1998-05-13 MX MX9803792A patent/MX9803792A/es unknown
- 1998-11-19 CY CY9800046A patent/CY2103B1/xx unknown
-
1999
- 1999-12-07 US US09/455,697 patent/US6117861A/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA969646B (en) | Protein kinase C inhibitor. | |
AU5324996A (en) | Protein kinase c inhibitors | |
CY2561B1 (en) | Protein kinase C inhibitors | |
ZA967315B (en) | Biphenylamides. | |
AU7631496A (en) | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | |
EP0835109A4 (en) | PYRIDINONE-BASED THROMBIN INHIBITORS | |
ZA9810219B (en) | Benzothiazole protein tyrosine kinase inhibitors. | |
ZA9610858B (en) | Heteroclyclic compounds. | |
MX213417B (es) | Fenilpiridazinonas. | |
ZA966075B (en) | Protein formulation. | |
EP0630245A4 (en) | PROTEIN KINASE C INHIBITOR. | |
ZA964468B (en) | Triazolylmethyl-cyclopentanols. | |
ZA961955B (en) | Indazolecarboxamides. | |
AU6882598A (en) | Protein kinase inhibitor | |
DE69610844D1 (en) | Hydroformylierungsverfahren. | |
ZA966399B (en) | Endothelin-receptor-antagonists. | |
ZA964560B (en) | Anit-viral compounds. | |
ZA949611B (en) | Protein kinase C inhibitors | |
ZA968185B (en) | Protein. | |
ZA966933B (en) | Endothelin-receptor-antagonists. | |
ZA966750B (en) | Halogenobenzimidazoles. | |
ZA967314B (en) | Carbamoylcarboxamides. | |
ZA969560B (en) | Substituted 1-methyl-3-phenylpyrazoles. | |
IL122092A0 (en) | Protein kinase C inhibitors | |
SI0657458T1 (en) | Protein kinase C inhibitors |